Janney Montgomery Scott Starts Jazz Pharmaceuticals (JAZZ) at Neutral
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- S&P 500 ends up slightly with boost from financials; Netflix up late
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- La Quinta Holdings (LQ) Gains on Plan to Split in Two
- After-Hours Stock Movers 01/18: (OCLR) (CSX) (NFLX) Higher; (AMDA) (RCII) (ZYNE) Lower (more...)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Janney Montgomery Scott initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Neutral rating.
Shares of Jazz Pharmaceuticals closed at $129.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SunTrust Robinson Humphrey Reacts To Favorable FDA Decision For Jazz Pharmaceuticals (JAZZ)
- Deutsche Bank Reacts To Favorable FDA Decision For Jazz Pharmaceuticals (JAZZ)
- Janney Montgomery Scott Starts Ampco-Pittsburgh (AP) at Neutral
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesJanney Montgomery Scott
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!